Clinical trials: Pregnancy Complication
Polycystic Ovary Syndrome
A Study to Explore Correlation Between Symptoms and Signs of Polycystic Ovarian Syndrome (PCOS) and Risk of Over-response to Ovarian Stimulation
This is a Phase IV, prospective, observational, single arm, multicenter trial to identify the population at high risk of overstimulation associated with signs and symptoms of PCOS and examines the utility of 12.5 international…
- Trial name
- ARTIST (NCT02607293)
- Testing
- Gonal-f®, Long GnRH agonist, GnRH antagonist
- Where
- Germany
- Volunteers
- 1,064 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Cervical Disease
Initial Study With the CNDS Advanced Cervical Scan to Recalibrate Spectral Data for Use in Future Screening Studies
The purpose of this study is to evaluate whether fluorescence and reflectance spectroscopy can improve the ability to detect the presence of premalignant lesions on the cervix.
- Trial name
- Spectral (NCT02217215)
- Testing
- CNDS Advanced Cervical Scan
- Where
- United States
- Volunteers
- 800 people, healthy volunteers welcome
- Sponsor
- Guided Therapeutics
CHF, Renal Disease
Validation of a Sensor for Non-Invasive Measurements
Subjects will be measured with both a sensor and a reference device
- Conditions
- CHF, Renal Disease, Hypertension
- Trial name
- NCT03463148
- Where
- United States
- Volunteers
- 136 people
- Sponsor
- Baxter Healthcare Corporation
Renal Impairment
Study to Evaluate the Pharmacokinetics of Lemborexant (E2006) and Its Metabolites in Subjects With Normal Renal Function or With Severe Renal Impairment
This study will be conducted to assess the effect of severe renal impairment on the pharmacokinetics of lemborexant after a single-dose administration.
- Trial name
- NCT03443063
- Testing
- Lemborexant
- Where
- 2 sites in United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Eisai Inc.
Cardiovascular Disease, Chronic Kidney Failure
Effect of HCO1100 on Cardiovascular Function
The purpose of this study is to determine whether high porous membranes are effective in the treatment of cardiovascular events in chronic dialysis patients.
- Trial name
- HicoCARD (NCT01363921)
- Testing
- HCO 1100
- Where
- Germany
- Volunteers
- 10 people
- Sponsor
- Vantive Health LLC
Uterine Cervical Neoplasm
Validation of BD Onclarity™ HPV Assay With PreservCyt® -ASCUS Samples
The purpose of the study is to compare the results of the Becton Dickinson (BD) Human Papilloma Virus (HPV) Assay on the Viper LT instrument from Liquid-based cytology media diluted in HPV diluent to adjudicated histology results…
- Trial name
- NCT03020121
- Testing
- Colposcopy/biopsy
- Where
- 12 sites in United States, Canada
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Becton, Dickinson and Company
Advanced Solid Tumors
Study of Intermittent OSI-906 Dosing
Multicenter, open-label, phase 1, cohort dose escalation study to determine the maximum tolerated dose (MTD) of 3 intermittent OSI-906 dosing schedules.
- Trial name
- NCT00514306
- Testing
- OSI-906
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 79 people
- Sponsor
- Astellas Pharma Inc
Stress Urinary Incontinence, Mixed Urinary Incontinence
Comparing Use of a Digital Health System of Pelvic Floor Exercise Program to Kegel Exercises in Stress Urinary Incontinence
A randomized controlled trial for patients with stress urinary incontinence or stress-dominant mixed incontinence. Subjects will be randomized to 8-weeks of home kegel exercises or 8 weeks of pelvic floor muscle exercises using…
- Trial name
- NCT03632447
- Testing
- Leva, PFDx
- Where
- 7 sites in United States
- Volunteers
- 77 people
- Sponsor
- Renovia, Inc.
Vulvovaginal Atrophy
Study to Evaluate Safety and Efficacy of WC3011 (Estradiol Vaginal Cream) in Postmenopausal Women With Dyspareunia
The purpose of the study is to determine if WC3011 is safe and effective in treating the symptom of painful intercourse secondary to vulvovaginal atrophy as measured by participant self-assessment when compared to vehicle.
- Trial name
- NCT01845649
- Testing
- WC3011 Estradiol Vaginal Cream, Vehicle
- Where
- 57 sites in United States
- Volunteers
- 550 people
- Sponsor
- Warner Chilcott
IgA Nephropathy
Trial of Sibeprenlimab in Children and Adolescents With Immunoglobulin A Nephropathy (IgAN)
This Phase 3, open-label study will evaluate the efficacy, safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of sibeprenlimab administered subcutaneously every 4 weeks in pediatric…
- Trial name
- NCT07770815
- Testing
- Sibeprenlimab, Standard of care
- Volunteers
- 24 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Advanced Solid Tumors, Breast Cancer Recurrent
First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers
The goal of this study is to identify a safe and tolerated dose of the orally administered DHX9 inhibitor ATX-559. In addition, this study will evaluate the pharmacokinetics, pharmacodynamics and preliminary antitumor activity of…
- Conditions
- Advanced Solid Tumors, Breast Cancer Recurrent, Colorectal Cancer Metastatic, Colon Cancer
- Trial name
- NCT06625515
- Testing
- ATX-559
- Where
- 5 sites in United States
- Volunteers
- 17 people
- Sponsor
- Accent Therapeutics
Ovarian Neoplasms
A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer
The purpose of this study is to determine if participants with platinum-refractory or platinum-resistant advanced ovarian cancer have a better outcome when treated with Olaratumab (IMC-3G3) in combination with Liposomal…
- Trial name
- NCT00913835
- Testing
- Olaratumab, liposomal doxorubicin
- Where
- 6 sites in United States
- Volunteers
- 125 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus, CKD and Albuminuria
A Study to Evaluate the Effect of Dapagliflozin With and Without Saxagliptin on Albuminuria, and to Investigate the Effect of Dapagliflozin and Saxagliptin on HbA1c in Patients With Type 2 Diabetes and CKD
The purpose of this clinical research study is to determine whether dapagliflozin alone or in combination with saxagliptin can decrease albuminuria and improve glycemic control in patients with Type 2 diabetes, albuminuria and…
- Trial name
- NCT02547935
- Testing
- Dapagliflozin 10 mg, Saxagliptin 2.5 mg
- Where
- 112 sites in United States, Australia and 7 more
- Volunteers
- 459 people
- Sponsor
- AstraZeneca
Non-muscle Invasive Bladder Cancer
A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer
The purpose of this study is to learn about the safety and effects of the study medicine (sasanlimab) in people with non-muscle invasive bladder cancer.
- Trial name
- CREST (NCT04165317)
- Testing
- PF-06801591, Bacillus Calmette-Guerin
- Where
- 196 sites in United States, Australia and 12 more
- Volunteers
- 1,068 people
- Sponsor
- Pfizer
Carcinoma, Renal Cell
A Study to Compare Tivozanib Hydrochloride to Sorafenib in Participants With Refractory Advanced Renal Cell Carcinoma (RCC)
This is a Phase 3, open-label, randomized, controlled, multi-national, multi-center, parallel-arm study comparing tivozanib to sorafenib in participants with refractory advanced renal cell carcinoma (RCC).
- Trial name
- NCT02627963
- Testing
- Tivozanib hydrochloride, Sorafenib
- Where
- 191 sites in United States, Belgium and 10 more
- Volunteers
- 350 people
- Sponsor
- AVEO Pharmaceuticals, Inc.
IgA Nephropathy
A Study of JADE101 in Participants With Immunoglobulin A Nephropathy
This open-label Phase 2 study will characterize the safety and efficacy of JADE101 in participants with IgA nephropathy, and the results will contribute to the overall clinical characterization of JADE101 in this patient…
- Trial name
- NCT07541287
- Testing
- JADE101
- Where
- 20 sites in United States, Australia and 3 more
- Volunteers
- 30 people
- Sponsor
- Jade Biosciences, Inc.
Metastatic Cancer, Cancer
A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer
The goal of this Phase 1 clinical research study is to find the highest safe dose of BIND-014 that can be given in the treatment of patients with advanced or metastatic cancer.
- Conditions
- Metastatic Cancer, Cancer, Solid Tumors
- Trial name
- NCT01300533
- Testing
- BIND-014
- Where
- 6 sites in United States
- Volunteers
- 58 people
- Sponsor
- BIND Therapeutics
Ureteral Calculi, Kidney Stones
Study of Silodosin to Facilitate Passage of Urinary Stones
The purpose of this study is to assess if patients treated with silodosin will have a higher spontaneous passage rate of their ureteral stone than those treated with placebo.
- Conditions
- Ureteral Calculi, Kidney Stones, Urolithiasis
- Trial name
- NCT01144949
- Testing
- silodosin
- Where
- 27 sites in United States
- Volunteers
- 239 people
- Sponsor
- Watson Pharmaceuticals
Endometrial Neoplasms, Endometrial Cancer
Symbiotic-GYN-18: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Advanced or Recurrent MMR-proficient Endometrial Cancer
This study is being conducted to assess whether the study medicine PF 08634404, given in combination with chemotherapy, improves outcomes compared with another medicine called pembrolizumab plus chemotherapy.
- Trial name
- NCT07578649
- Testing
- PF-08634404, Pembrolizumab, Standard of Care Chemotherapy
- Where
- 43 sites in United States, Australia and 2 more
- Volunteers
- 600 people
- Sponsor
- Pfizer
Solid Tumors
A Study to Assess the Safety, Pharmacokinetics, and Efficacy of Intravenous (IV) ABBV-303, as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181), in Adults With Advanced Solid Tumors
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess safety, tolerability, pharmacokinetics and preliminary efficacy of ABBV-303 as a monotherapy…
- Trial name
- NCT06158958
- Testing
- ABBV-303, Budigalimab
- Where
- 18 sites in United States, Israel and 1 more
- Volunteers
- 27 people
- Sponsor
- AbbVie